Research programme: antibacterials - Replidyne

Drug Profile

Research programme: antibacterials - Replidyne

Alternative Names: Bacterial DNA polymerase inhibitors - Replidyne; Bacterial DNA primase inhibitors - Replidyne; REP 6021; tRNA synthetase inhibitors - Replidyne

Latest Information Update: 02 Mar 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer Cardiovascular Systems
  • Class Guanidines; Pyrimidinones
  • Mechanism of Action DNA synthesis inhibitors; Enzyme inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Bacterial infections; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 27 Aug 2008 Suspended - Preclinical for Bacterial infections in USA (unspecified route)
  • 27 Aug 2008 Suspended - Preclinical for Meticillin-resistant Staphylococcus aureus infections in USA (Topical)
  • 12 Apr 2006 Data presented at the 231st American Chemical Society National Meeting (231st-ACS-2006) have been added to the Bacterial Infections antimicrobial activity section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top